Patient-specific factors predictive of warfarin dosage requirements.
about
VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarkerEthnicity-specific pharmacogenetics: the case of warfarin in African AmericansVitamin K intake, body mass index and warfarin maintenance doseEffect of age and sex on warfarin dosingPrevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.Warfarin and vitamin K intake in the era of pharmacogenetics.Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.The future prospects of pharmacogenetics in oral anticoagulation therapy.Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.Genetic warfarin dosing: tables versus algorithms.Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing.Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.Initiating warfarin therapy: 5 mg versus 10 mg.Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.Ethics and research assessing the relative roles of genes and the environment.The pharmacogenetics of coumarin therapy.Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.The future of warfarin pharmacogenetics in under-represented minority groups.Factors influencing warfarin response in hospitalized patients.Effect of patient-specific factors on weekly warfarin doseRace-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.Integrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report.Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.Patient factors that influence warfarin dose response.Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method.Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.The effect of carbamazepine on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population.Treatment of Suspected Pulmonary Embolism in a Super-Obese Individual.Genetic and clinical predictors of warfarin dose requirements in African Americans.A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms.Multivitamin supplements may affect warfarin anticoagulation in susceptible patients.Shifting paradigms in the pharmacogenetics of warfarin.The influence of ethnicity on warfarin dosage requirement.Search for predictors of nontherapeutic INR results with warfarin therapy.Factors influencing warfarin dose requirements in African-Americans.Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage.Improved control of oral anticoagulant dosing: a randomized controlled trial comparing two computer algorithms.
P2860
Q28476502-B7102E2D-E272-483F-8FF7-6D6037A81E71Q33591111-452983CF-CB08-4D52-AD2B-C949E909715EQ33684929-268CA367-43CE-4D81-A738-7D9EA676BFE7Q33921765-3E0D31B9-3F11-4F5F-A972-15EACC16C6A3Q33990441-AB619FF3-CCDE-4A0F-AE16-990B558206CFQ34026225-12F3A720-E486-4CFC-B812-0396C2392BB6Q34096562-ACDDD7CC-B96D-497A-9F92-2DB860E379DEQ34530230-F5793933-05EA-4D90-86D7-2E3116B71A4EQ34605304-BFEAABB1-9EF7-4F1B-9EC2-68C3EEAF990DQ35021027-9753169C-FC0D-4041-8179-D4DD029A23FCQ35037456-512D9AB1-658B-4099-A935-1EF3FB283F24Q35612111-7C6510F7-5E3B-452B-92BD-FAC92C9B0688Q35681000-BC7A1A21-BBE8-49D6-A2EA-DD5083AF0679Q35937712-E194CAA6-F25C-44BF-A0C4-18FC517AA7E9Q36044022-36507E00-DA7F-4A1F-A9F4-DBD5EFD21ECDQ36090392-F1AC9936-318C-4191-9162-2B7E27C9CB8FQ36192806-CA4D8C1E-9F83-4EAF-8E0E-4B768E797740Q36219235-89F5CF34-439D-43A9-BFF8-07E9C224394DQ36294461-AFFBD187-D6DC-4E73-B79D-7486B88392CCQ36346124-2C51D138-9A25-46CF-BE20-C71047501459Q36661285-5411B9F5-9CF9-4EC1-8993-B9F686C13DDDQ36717256-09320FC3-A2AC-4EF9-B46D-A2E9253E9D2FQ36762797-F623E744-795C-45AD-AE9A-59E7972CA4F3Q36965475-D4F47653-89B9-4870-8EE9-B9093F914D97Q37353441-BE8886C5-2DD4-4111-883F-FF6913375F4FQ37867275-A8D26F38-F94D-430F-8566-BF91E354ECE1Q38858766-B7EE2437-7CE6-426B-A77D-508FFFF17633Q38897899-F5140DCC-FFC5-46CA-8466-716918E01FAFQ38897904-C813C36A-54C5-4F43-92CD-E70C4D4BC3CBQ40081501-FF4D6391-F792-418D-B252-6E8C99C1608DQ43116838-8C63495E-78E3-49FE-A201-5276E901507EQ43195085-BB4BD017-9752-4D15-8E80-9FEE9E11E53AQ43857194-F2F8FEAF-D17A-4D42-8F39-9AD16FA18B9FQ44622773-55D86015-8202-4D57-B444-2074C6A53BE0Q46316268-3C2D4A78-F00F-47B4-9427-753539A63A9CQ46458606-EE4AE153-51E8-47E6-8AFA-2EB3D133CB45Q46803803-1E96595F-9555-4447-973B-5C809CC8EED0Q46885448-F68E01E1-0939-4C0B-9C8C-E41D43B8BDD2Q49378467-6C764C1F-3D21-4160-9E59-54BB882E81F2Q51008969-D5BC992E-767E-4A68-AAA4-A2F7FDE4B10C
P2860
Patient-specific factors predictive of warfarin dosage requirements.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Patient-specific factors predictive of warfarin dosage requirements.
@en
Patient-specific factors predictive of warfarin dosage requirements.
@nl
type
label
Patient-specific factors predictive of warfarin dosage requirements.
@en
Patient-specific factors predictive of warfarin dosage requirements.
@nl
prefLabel
Patient-specific factors predictive of warfarin dosage requirements.
@en
Patient-specific factors predictive of warfarin dosage requirements.
@nl
P2093
P2860
P356
P1476
Patient-specific factors predictive of warfarin dosage requirements.
@en
P2093
M Elisabeth Moore
Mary H Parker
Randall K Absher
P2860
P304
P356
10.1345/APH.1C025
P407
P577
2002-10-01T00:00:00Z